KKR makes $1.2 billion offer for Sweden's Biotage - Finance news and analysis from Global Banking & Finance Review
Finance

KKR makes $1.2 billion offer for Sweden's Biotage

Published by Global Banking & Finance Review

Posted on April 22, 2025

1 min read

· Last updated: April 22, 2025

Add as preferred source on Google

KKR Proposes $1.2 Billion Acquisition of Sweden's Biotage

COPENHAGEN (Reuters) -Sweden's Biotage said on Tuesday that KKR had made a cash offer for the Swedish biotechnology firm, valuing it at around 11.6 billion Swedish crowns ($1.22 billion).

The offer price of 145 crowns per share represents a premium of 60.1% compared with its closing share price on April 17.

Biotage's board of directors unanimously recommended to its shareholders that they accept the offer, the company said in a statement.

Gamma Biosciences, which is controlled by KKR, is the company's biggest shareholder owning a 17% stake.

($1 = 9.5059 Swedish crowns)

(Reporting by Stine Jacobsen, editing by Terje Solsvik)

Key Takeaways

  • KKR offers $1.2 billion for Biotage.
  • The offer includes a 60.1% premium on share price.
  • Biotage's board recommends shareholders accept the offer.
  • Gamma Biosciences, controlled by KKR, holds a 17% stake.
  • The deal values Biotage at 11.6 billion Swedish crowns.

Frequently Asked Questions

What is the main topic?
The article discusses KKR's $1.2 billion cash offer for Sweden's Biotage, highlighting the strategic implications for shareholders.
What is the offer's premium?
The offer represents a 60.1% premium compared to Biotage's closing share price on April 17.
Who is Biotage's biggest shareholder?
Gamma Biosciences, controlled by KKR, is Biotage's biggest shareholder with a 17% stake.

Related Articles

More from Finance

Explore more articles in the Finance category